413 related articles for article (PubMed ID: 18957481)
1. Antimyeloperoxidase antibodies are a useful marker of disease activity in antineutrophil cytoplasmic antibody-associated vasculitides.
Terrier B; Saadoun D; Sène D; Ghillani P; Amoura Z; Deray G; Fautrel B; Piette JC; Cacoub P
Ann Rheum Dis; 2009 Oct; 68(10):1564-71. PubMed ID: 18957481
[TBL] [Abstract][Full Text] [Related]
2. Prediction of relapses in PR3-ANCA-associated vasculitis by assessing responses of ANCA titres to treatment.
Sanders JS; Huitma MG; Kallenberg CG; Stegeman CA
Rheumatology (Oxford); 2006 Jun; 45(6):724-9. PubMed ID: 16399845
[TBL] [Abstract][Full Text] [Related]
3. Predictive value of antineutrophil cytoplasmic antibodies in small-vessel vasculitis.
Lurati-Ruiz F; Spertini F
J Rheumatol; 2005 Nov; 32(11):2167-72. PubMed ID: 16265696
[TBL] [Abstract][Full Text] [Related]
4. [Usefulness of anti-neutrophil cytoplasmic antibodies, anti-proteinase 3 and anti-myeloperoxidase in management of small vessel vasculitis].
Ara J; Mirapeix E; Rodríguez R; Pascual J; Alvarez L; Darnell A
Med Clin (Barc); 1998 Oct; 111(14):536-8. PubMed ID: 9859079
[TBL] [Abstract][Full Text] [Related]
5. Antineutrophil cytoplasm antibodies in systemic polyarteritis nodosa with and without hepatitis B virus infection and Churg-Strauss syndrome--62 patients.
Guillevin L; Visser H; Noel LH; Pourrat J; Vernier I; Gayraud M; Oksman F; Lesavre P
J Rheumatol; 1993 Aug; 20(8):1345-9. PubMed ID: 7901412
[TBL] [Abstract][Full Text] [Related]
6. A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies.
Jayne D; Rasmussen N; Andrassy K; Bacon P; Tervaert JW; Dadoniené J; Ekstrand A; Gaskin G; Gregorini G; de Groot K; Gross W; Hagen EC; Mirapeix E; Pettersson E; Siegert C; Sinico A; Tesar V; Westman K; Pusey C;
N Engl J Med; 2003 Jul; 349(1):36-44. PubMed ID: 12840090
[TBL] [Abstract][Full Text] [Related]
7. Intravenous immunoglobulins for relapses of systemic vasculitides associated with antineutrophil cytoplasmic autoantibodies: results of a multicenter, prospective, open-label study of twenty-two patients.
Martinez V; Cohen P; Pagnoux C; Vinzio S; Mahr A; Mouthon L; Sailler L; Delaunay C; Sadoun A; Guillevin L;
Arthritis Rheum; 2008 Jan; 58(1):308-17. PubMed ID: 18163506
[TBL] [Abstract][Full Text] [Related]
8. Long-term observation of patients with anti-neutrophil cytoplasmic antibody-associated vasculitis treated with rituximab.
Stasi R; Stipa E; Del Poeta G; Amadori S; Newland AC; Provan D
Rheumatology (Oxford); 2006 Nov; 45(11):1432-6. PubMed ID: 16632482
[TBL] [Abstract][Full Text] [Related]
9. Positive classic antineutrophil cytoplasmic antibody (C-ANCA) titer at switch to azathioprine therapy associated with relapse in proteinase 3-related vasculitis.
Slot MC; Tervaert JW; Boomsma MM; Stegeman CA
Arthritis Rheum; 2004 Apr; 51(2):269-73. PubMed ID: 15077271
[TBL] [Abstract][Full Text] [Related]
10. Role of antineutrophil cytoplasmic antibodies and glomerular basement membrane antibodies in the diagnosis and monitoring of systemic vasculitides.
Sinclair D; Stevens JM
Ann Clin Biochem; 2007 Sep; 44(Pt 5):432-42. PubMed ID: 17761028
[TBL] [Abstract][Full Text] [Related]
11. Outcome and prognostic factors during the course of primary small-vessel vasculitides.
Pavone L; Grasselli C; Chierici E; Maggiore U; Garini G; Ronda N; Manganelli P; Pesci A; Rioda WT; Tumiati B; Pavesi G; Vaglio A; Buzio C;
J Rheumatol; 2006 Jul; 33(7):1299-306. PubMed ID: 16783858
[TBL] [Abstract][Full Text] [Related]
12. Variations in performance characteristics of commercial enzyme immunoassay kits for detection of antineutrophil cytoplasmic antibodies: what is the optimal cut off?
Holle JU; Hellmich B; Backes M; Gross WL; Csernok E
Ann Rheum Dis; 2005 Dec; 64(12):1773-9. PubMed ID: 15843447
[TBL] [Abstract][Full Text] [Related]
13. Microscopic polyangiitis: clinical and laboratory findings in eighty-five patients.
Guillevin L; Durand-Gasselin B; Cevallos R; Gayraud M; Lhote F; Callard P; Amouroux J; Casassus P; Jarrousse B
Arthritis Rheum; 1999 Mar; 42(3):421-30. PubMed ID: 10088763
[TBL] [Abstract][Full Text] [Related]
14. Drug-associated antineutrophil cytoplasmic antibody-positive vasculitis: prevalence among patients with high titers of antimyeloperoxidase antibodies.
Choi HK; Merkel PA; Walker AM; Niles JL
Arthritis Rheum; 2000 Feb; 43(2):405-13. PubMed ID: 10693882
[TBL] [Abstract][Full Text] [Related]
15. [Treatment of ANCA associated systemic necrotizing vasculitides].
Guillevin L
Bull Acad Natl Med; 2008; 192(6):1175-87; discussion 1188. PubMed ID: 19235481
[TBL] [Abstract][Full Text] [Related]
16. Clinical and pathological characteristics and outcomes of Chinese patients with primary anti-neutrophil cytoplasmic antibodies-associated systemic vasculitis with immune complex deposition in kidney.
Yu F; Chen M; Wang SX; Zou WZ; Zhao MH; Wang HY
Nephrology (Carlton); 2007 Feb; 12(1):74-80. PubMed ID: 17295665
[TBL] [Abstract][Full Text] [Related]
17. ANCA-associated renal vasculitis at the end of the twentieth century--a disease of older patients.
Harper L; Savage CO
Rheumatology (Oxford); 2005 Apr; 44(4):495-501. PubMed ID: 15613403
[TBL] [Abstract][Full Text] [Related]
18. Value of a new automated fluorescence immunoassay (EliA) for PR3 and MPO-ANCA in monitoring disease activity in ANCA-associated systemic vasculitis.
Sinico RA; Radice A; Corace C; DI Toma L; Sabadini E
Ann N Y Acad Sci; 2005 Jun; 1050():185-92. PubMed ID: 16014533
[TBL] [Abstract][Full Text] [Related]
19. Baseline features and initial treatment as predictors of remission and relapse in Wegener's granulomatosis.
Koldingsnes W; Nossent JC
J Rheumatol; 2003 Jan; 30(1):80-8. PubMed ID: 12508394
[TBL] [Abstract][Full Text] [Related]
20. [Pathogenic role of antimyeloperoxidase antibodies].
Guilpain P; Maldini C; Guillevin L
Rev Med Interne; 2011 Jul; 32(7):411-5. PubMed ID: 20633964
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
